Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Oncologic Outcomes of Young Breast Cancer Patients According to Tumor Biology
by
Lukac, Stefan
, Otremba, Burkhard
, Willborn, Kay C.
, Torres-de la Roche, Luz Angela
, De Wilde, Rudy Leon
, Henzler, Marijana
, Janni, Wolfgang
, Huober, Jens
, Shi, Wenjie
in
Age
/ Analysis
/ Biology
/ Body mass index
/ Breast cancer
/ Breast carcinoma
/ Cancer
/ Cancer patients
/ Cancer therapies
/ Care and treatment
/ Chemotherapy
/ Development and progression
/ Disease
/ Disease resistance
/ ErbB-2 protein
/ Medical prognosis
/ Metabolism
/ Oncology, Experimental
/ Patient outcomes
/ Patients
/ Pertuzumab
/ Statistical analysis
/ Survival
/ Tumors
/ Womens health
2025
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Oncologic Outcomes of Young Breast Cancer Patients According to Tumor Biology
by
Lukac, Stefan
, Otremba, Burkhard
, Willborn, Kay C.
, Torres-de la Roche, Luz Angela
, De Wilde, Rudy Leon
, Henzler, Marijana
, Janni, Wolfgang
, Huober, Jens
, Shi, Wenjie
in
Age
/ Analysis
/ Biology
/ Body mass index
/ Breast cancer
/ Breast carcinoma
/ Cancer
/ Cancer patients
/ Cancer therapies
/ Care and treatment
/ Chemotherapy
/ Development and progression
/ Disease
/ Disease resistance
/ ErbB-2 protein
/ Medical prognosis
/ Metabolism
/ Oncology, Experimental
/ Patient outcomes
/ Patients
/ Pertuzumab
/ Statistical analysis
/ Survival
/ Tumors
/ Womens health
2025
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Oncologic Outcomes of Young Breast Cancer Patients According to Tumor Biology
by
Lukac, Stefan
, Otremba, Burkhard
, Willborn, Kay C.
, Torres-de la Roche, Luz Angela
, De Wilde, Rudy Leon
, Henzler, Marijana
, Janni, Wolfgang
, Huober, Jens
, Shi, Wenjie
in
Age
/ Analysis
/ Biology
/ Body mass index
/ Breast cancer
/ Breast carcinoma
/ Cancer
/ Cancer patients
/ Cancer therapies
/ Care and treatment
/ Chemotherapy
/ Development and progression
/ Disease
/ Disease resistance
/ ErbB-2 protein
/ Medical prognosis
/ Metabolism
/ Oncology, Experimental
/ Patient outcomes
/ Patients
/ Pertuzumab
/ Statistical analysis
/ Survival
/ Tumors
/ Womens health
2025
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Oncologic Outcomes of Young Breast Cancer Patients According to Tumor Biology
Journal Article
Oncologic Outcomes of Young Breast Cancer Patients According to Tumor Biology
2025
Request Book From Autostore
and Choose the Collection Method
Overview
Background/Objectives: Young women frequently present with more aggressive breast cancer tumors. This retrospective study analyzed the oncological outcomes of patients under the age of 40 according to the tumor biology. Methods: Group comparisons were performed via the log-rank test. Recurrence and survival rates are presented according to the Kaplan–Meier method. Results: In total, 88 women (mean age 36) were included, but two presented with bilateral cancer, resulting in 90 tumors. Triple-negative carcinoma was most common, with 26.7% (n = 24); 11.1% (n = 10) were luminal A; 23.3% (n = 21) were luminal B HER2-negative; 15.6% (n = 14) were luminal B HER2-positive; and 6.7% (n = 6) were HER2-positive (non-luminal). Moreover, 26.1% (n = 23) of patients experienced recurrence (mean 40 months), with the highest recurrence rate in the HER2-positive (50%) and triple-negative (30.4%) groups. The 3- and 5-year recurrence-free survival rates were 84.9% and 77.3%, and the overall survival rates were 93.1% and 90.3%, respectively. No statistically significant differences in oncological outcomes were observed (p = 0.164). Conclusions: The results show that young women tend to have triple-negative and fast-growing breast carcinomas, with worse overall survival in the triple-negative group. More research is needed on the pathomechanisms of breast cancer development in young women, especially those leading to disease progression and resistance to therapy.
MBRLCatalogueRelatedBooks
Related Items
Related Items
We currently cannot retrieve any items related to this title. Kindly check back at a later time.
This website uses cookies to ensure you get the best experience on our website.